Thank you barnstormer. I believe the increase in the NWBO share price will gradually increase after the DCVax-L top line data (TLD) is officially released to the press by NWBio, and the DCVax-L Phase III trial results are printed in a top tier peer-reviewed medical journal.
Although, there has been a deliberate attempt by some to downplay the importance of the journal article, it will have a significant impact on validating and verifying the DCVax-L trial results, and on the subsequent NWBO share price increases. It will not be just the impact of the journal article by itself, it will be the cumulative impact of what the journal article represents, and what it allows and frees up NWBio to do after the journal article is published.
The official release of the TLD by NWBio, and the journal article will enable the following:
(1) The official end of the NWBio Quiet Period. NWBio will be able to publicly and freely discuss its progress, plans and timing for DCVax-L regulatory submissions in the US, UK, Canada, Germany and the rest of the EU.
(2) NWBio will be able to get the peer-reviewed DCVax-L Phase III clinical trial results to neuro-oncologists, and other GBM related key opinion leaders (KOLs) around the world.
(3) NWBio will be able to announce the DCVax-L Phase III clinical trial results to daily and weekly newspapers, national television networks and local television stations, medical news journals, and GBM / brain tumor patient advocacy and support groups around the world.
(4) NWBio will be able to announce the DCVax-L Phase III clinical trial results to financial newspapers (Wall Street Journal, Financial Times of London, etc.) financial journals (Forbes, Fortune, etc.), financial television networks (Bloomberg, CNBC, Fox Business, etc.) around the world.
AI
Market Data 
Markets 
